Orbimed Advisors - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$86,129,241
+21.0%
2,896,074
-26.7%
1.83%
+41.9%
Q2 2023$71,193,344
+12.2%
3,950,7960.0%1.29%
+3.5%
Q1 2023$63,449,784
+8.5%
3,950,796
+23.6%
1.25%
+11.3%
Q4 2022$58,502,831
-6.8%
3,196,8760.0%1.12%
-4.0%
Q3 2022$62,787,000
+5.3%
3,196,8760.0%1.17%
+8.0%
Q2 2022$59,622,000
-15.0%
3,196,8760.0%1.08%
-5.1%
Q1 2022$70,171,000
-22.7%
3,196,8760.0%1.14%
-2.6%
Q4 2021$90,823,000
+44.0%
3,196,876
+6.7%
1.17%
+68.5%
Q3 2021$63,084,000
+11.7%
2,996,8760.0%0.69%
+21.4%
Q2 2021$56,491,000
+34.3%
2,996,876
+8.8%
0.57%
+45.3%
Q1 2021$42,075,000
+8.3%
2,753,5670.0%0.39%
+15.6%
Q4 2020$38,853,000
-10.0%
2,753,5670.0%0.34%
-37.3%
Q3 2020$43,148,000
-10.6%
2,753,5670.0%0.54%
-20.2%
Q2 2020$48,242,000
+60.9%
2,753,567
+35.0%
0.68%
+34.7%
Q1 2020$29,977,000
-41.4%
2,039,2820.0%0.50%
-31.0%
Q4 2019$51,166,000
+66.8%
2,039,2820.0%0.73%
+25.4%
Q3 2019$30,671,000
-39.8%
2,039,2820.0%0.58%
-26.3%
Q2 2019$50,982,000
+17.0%
2,039,282
+6.5%
0.79%
+17.2%
Q1 2019$43,569,000
-24.1%
1,914,2820.0%0.67%
-36.5%
Q4 2018$57,409,000
+4.7%
1,914,2820.0%1.06%
+60.7%
Q3 2018$54,844,0001,914,2820.66%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Saturn V Capital Management LP 1,126,579$33,504,45914.02%
New Leaf Venture Partners, L.L.C. 141,000$4,193,3405.38%
First Light Asset Management, LLC 1,583,329$47,088,2044.47%
Paradigm Biocapital Advisors LP 2,178,737$64,795,6384.40%
Bain Capital Life Sciences Investors, LLC 1,275,552$37,934,9164.24%
Altium Capital Management LP 262,000$7,791,8804.06%
5AM Venture Management, LLC 462,286$13,748,3863.96%
MPM BioImpact LLC 479,053$14,247,0363.80%
Affinity Asset Advisors, LLC 450,000$13,383,0003.76%
Opaleye Management Inc. 370,000$11,003,8003.58%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders